Enterprise Value
1.398B
Cash
355.9M
Avg Qtr Burn
-59.76M
Short % of Float
7.70%
Insider Ownership
7.98%
Institutional Own.
82.78%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Roxadustat (ROW) Details Chronic kidney disease, Anemia | Approved Quarterly sales | |
Roxadustat (U.S.) Details Chronic kidney disease, Anemia | sNDA Submission | |
Phase 3 Data readout | ||
Phase 3 Data readout | ||
Roxadustat Details Chemotherapy Induced Anemia | Phase 3 Data readout | |
Phase 3 Data readout | ||
Roxadustat Details Myelodysplastic syndrome, Anemia | Phase 3 Update | |
Pamrevlumab Details COVID-19, Infectious disease | Failed Discontinued |